Abstract
In highly experienced HIV-1-infected patients, a ritonavir-boosted darunavir-containing regimen was associated with dramatic immunological and virological efficacy. Patients harbouring viruses with amprenavir-specific resistance profiles, such as I50V or V32I + I47V, failed on a darunavir/ritonavir-containing regimen. These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy.
MeSH terms
-
CD4 Lymphocyte Count
-
Carbamates / therapeutic use*
-
Darunavir
-
Drug Resistance, Viral / genetics
-
Drug Therapy, Combination
-
Furans
-
HIV Infections / drug therapy*
-
HIV Infections / genetics
-
HIV Infections / virology
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / genetics*
-
Humans
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Risk Factors
-
Ritonavir / therapeutic use
-
Sulfonamides / therapeutic use*
-
Treatment Failure
-
Viral Load
Substances
-
Carbamates
-
Furans
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Sulfonamides
-
amprenavir
-
Ritonavir
-
Darunavir